Article Information
PubMed
Print ISSN
Online ISSN
History
- Received August 9, 2006
- Accepted September 29, 2006
- Published online December 27, 2006.
Article Versions
- Earlier version (October 4, 2006 - 07:55).
- You are viewing the most recent version of this article.
Copyright & Usage
The American Society for Pharmacology and Experimental Therapeutics
Author Information
- Rob Webster,
- Eric Didier,
- Philip Harris,
- Ned Siegel,
- Jeanne Stadler,
- Lorraine Tilbury and
- Dennis Smith
- Pharmacokinetics, Dynamics and Metabolism (R.W., D.S.) and Clinical Research and Development (E.D., P.H.), Pfizer Global Research and Development Sandwich, Kent, United Kingdom; Pfizer Global Research and Development, Amboise Cedex, France (J.S., L.T.); and Pfizer Global Research and Development, Chesterfield, Missouri (N.S.)
- Address correspondence to:
Rob Webster, Pfizer Global Research and Development, Pharmacokinetic, Dynamics and Metabolism (IPC 351), Sandwich, Kent, CT13 9NJ, UK. E-mail: rob.webster{at}pfizer.com
Statistics from Altmetric.com
Article usage
In this issue
Jump to section
- Article
- Abstract
- Toxicology of Polyethylene Glycol in Animals
- Toxicology of PEGylated Molecules in Animals
- Clearance of Polyethylene Glycol by Metabolism
- Excretion of Unchanged Polyethylene Glycol in the Urine and Bile: The Major Route of PEG Clearance?
- Likely Clearance Mechanisms for PEG Associated with PEGylated Proteins
- PEG Exposure in Humans
- Feasibility of Metabolism Studies with PEGylated Materials
- Conclusions
- Footnotes
- References
- Figures & Data
- Info & Metrics
- eLetters
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement